Biological Drivers of IMiD‐Induced Peripheral Neuropathy in Multiple Myeloma
ABSTRACT The introduction of immunomodulatory drugs (IMiDs), such as thalidomide, lenalidomide and pomalidomide, have led to significant improvements in multiple myeloma (MM) treatment. Many patients now live 10 years or longer with their disease, making treatment‐related side effects increasingly important.
Sina A. Beer +2 more
wiley +1 more source
A rabbit anti-human CD38 antibody for eliminating daratumumab and isatuximab interference in immunohematology testing. [PDF]
Zhang L +9 more
europepmc +1 more source
Early-Stage B-cells Predict Relapse After Rituximab Treatment in Patients With Membranous Nephropathy. [PDF]
Cheddadi Y +6 more
europepmc +1 more source
Perioperative immune dynamics during cardiopulmonary bypass and association with major adverse postoperative events. [PDF]
Cheng Z +9 more
europepmc +1 more source
The Level and Clinical Significance of B Lymphocytes and Immune Molecules (IL-4, IL-10, BAFF, and IgD) in Psoriasis. [PDF]
Wu B +7 more
europepmc +1 more source
Evaluating the utility of a nanoscale flow cytometer for detection of surface proteins on HIV and extracellular vesicles. [PDF]
Burnie J +7 more
europepmc +1 more source
Cluster of differentiation 38 monoclonal antibody therapy in the treatment of multiple myeloma: a systematic review and meta-analysis. [PDF]
Guo YJ, Tian ZZ, Zhang XF, Zhu ZJ.
europepmc +1 more source
Plenary Abstracts Session & Oral Presentations
HemaSphere, Volume 10, Issue S1, June 2026.
wiley +1 more source

